Zenas BioPharma, Inc. Common Stock (ZBIO) — Cash Flow-to-Debt Ratio
Zenas BioPharma, Inc. Common Stock (ZBIO) has a Cash Flow-to-Debt Ratio of -0.37x as of December 2025, meaning its operating cash flow of $-52.41 Million could theoretically repay 0% of its total liabilities ($141.50 Million) in one year. See ZBIO cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Zenas BioPharma, Inc. Common Stock Cash Flow-to-Debt Ratio (2022–2025)
Historical debt coverage capacity for Zenas BioPharma, Inc. Common Stock across 4 annual periods. Also explore ZBIO year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Zenas BioPharma, Inc. Common Stock (2022–2025)
Year-by-year debt coverage analysis for Zenas BioPharma, Inc. Common Stock. For market capitalisation and broader financial context, see how much is Zenas BioPharma, Inc. Common Stock worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.22x | $-172.33 Million | $141.50 Million | ▲ +41.5% |
| 2024 | -2.08x | $-119.67 Million | $57.51 Million | ▼ -1903.3% |
| 2023 | -0.10x | $-30.53 Million | $293.90 Million | ▲ +57.8% |
| 2022 | -0.25x | $-65.65 Million | $266.87 Million | — |